Patient Characteristics, Injected Doses, and 68Ga-NeoBOMB1 Lesion Uptake
| Participant | Age (y) | Sex | Primary | Year of first diagnosis | Current status | Current treatment | Body weight (kg) | Injected activity (MBq) | 68Ga-NeoBOMB1 uptake | |
| Primary/local recurrence | Metastases | |||||||||
| 1 | 76 | F | Duodenum | 2003 | Omental and liver metastasis | Sunitinib | 68 | 179 | 0/0 (n/a) | 2/2 (100%) |
| 2 | 73 | F | Ileum | 2012 | Liver metastases | Sunitinib | 48 | 127 | 0/0 (n/a) | 0/1 (0%) |
| 3 | 75 | M | Duodenum | 2016 | Liver and lung metastases | Sunitinib | 68 | 214 | 0/0 (n/a) | 2/2 (100%) |
| 4 | 83 | F | Stomach | 2014 | Liver metastases, local recurrence | Imatinib | 59 | 158 | 1/1 (100%) | 0/3 (0%) |
| 5 | 50 | F | Stomach | 2013 | Local recurrence, liver and peritoneal metastases | none | 52 | 169 | 2/2 (100%) | 1/6 (16.6%) |
| 6 | 55 | M | Ileum | 2014 | Liver metastasis | Sunitinib | 66 | 199 | 0/0 (n/a) | 4/4 (100%) |